Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Pharmaceutics 2013, 5(1), 127-167; doi:10.3390/pharmaceutics5010127
Review

From Molecular to Nanotechnology Strategies for Delivery of Neurotrophins: Emphasis on Brain-Derived Neurotrophic Factor (BDNF)

1,2
, 1,2,*  and 1,2
Received: 13 November 2012; in revised form: 30 January 2013 / Accepted: 5 February 2013 / Published: 8 February 2013
(This article belongs to the Special Issue Drug Delivery Using Nanotechnology)
View Full-Text   |   Download PDF [809 KB, uploaded 8 February 2013]
Abstract: Neurodegenerative diseases represent a major public health problem, but beneficial clinical treatment with neurotrophic factors has not been established yet. The therapeutic use of neurotrophins has been restrained by their instability and rapid degradation in biological medium. A variety of strategies has been proposed for the administration of these leading therapeutic candidates, which are essential for the development, survival and function of human neurons. In this review, we describe the existing approaches for delivery of brain-derived neurotrophic factor (BDNF), which is the most abundant neurotrophin in the mammalian central nervous system (CNS). Biomimetic peptides of BDNF have emerged as a promising therapy against neurodegenerative disorders. Polymer-based carriers have provided sustained neurotrophin delivery, whereas lipid-based particles have contributed also to potentiation of the BDNF action. Nanotechnology offers new possibilities for the design of vehicles for neuroprotection and neuroregeneration. Recent developments in nanoscale carriers for encapsulation and transport of BDNF are highlighted.
Keywords: neurotrophin BDNF delivery; therapeutic protein encapsulation; lipid nanocarriers; cubosomes; neurotrophic gene vectors; peptide mimetics; TrkB receptor; neurodegenerative disease therapy neurotrophin BDNF delivery; therapeutic protein encapsulation; lipid nanocarriers; cubosomes; neurotrophic gene vectors; peptide mimetics; TrkB receptor; neurodegenerative disease therapy
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Géral, C.; Angelova, A.; Lesieur, S. From Molecular to Nanotechnology Strategies for Delivery of Neurotrophins: Emphasis on Brain-Derived Neurotrophic Factor (BDNF). Pharmaceutics 2013, 5, 127-167.

AMA Style

Géral C, Angelova A, Lesieur S. From Molecular to Nanotechnology Strategies for Delivery of Neurotrophins: Emphasis on Brain-Derived Neurotrophic Factor (BDNF). Pharmaceutics. 2013; 5(1):127-167.

Chicago/Turabian Style

Géral, Claire; Angelova, Angelina; Lesieur, Sylviane. 2013. "From Molecular to Nanotechnology Strategies for Delivery of Neurotrophins: Emphasis on Brain-Derived Neurotrophic Factor (BDNF)." Pharmaceutics 5, no. 1: 127-167.



Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert